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Available online 23 February 2008The formation of oxidised low density lipoprotein (LDL) within the atherosclerotic plaque appears to be a
factor in the development of advanced atherosclerotic plaques. LDL oxidation is dependent on the balance of
oxidants and antioxidants within the intima. In addition to producing various oxidants, human macrophages
release 7,8-dihydroneopterin which in vivo is oxidised to the inﬂammation marker neopterin. Using
macrophage-like THP-1 cells and human monocyte-derived macrophages, we demonstrate that 7,8-
dihydroneopterin is a potent inhibitor of cell-mediated LDL oxidation. 7,8-Dihydroneopterin scavenges the
chain propagating lipid peroxyl radical, inhibiting both lipid and protein hydroperoxide formation. A
signiﬁcant amount of the hydroperoxide formed during cell-mediated LDL oxidation was protein
hydroperoxide. 7,8-Dihydroneopterin oxidation to 7,8-dihydroxanthopterin was only observed in the
presence of both cells and LDL, showing that 7,8-dihydroneopterin had no effect on initiating oxidant
generation by the cells. 7,8-Dihydroneopterin did not regenerate α-tocopherol but competed with it for the
lipid peroxyl radical. Although stimulation of both cell types with γ-interferon failed to produce sufﬁcient 7,8-
dihydroneopterin to inhibit LDL oxidation in tissue culture, analysis of advanced atherosclerotic plaque
removed from patients showed that total neopterin levels could reach low micromolar concentrations. This
suggests that 7,8-dihydroneopterin synthesis bymacrophages could play a signiﬁcant role in the development
of atherosclerotic plaques.
© 2008 Elsevier B.V. All rights reserved.Keywords:
Macrophage
Low density lipoprotein
Protein oxidation
Lipid oxidation
Neopterin
Antioxidant
Inﬂammation
Atherosclerosis1. Introduction
Oxidised low density lipoprotein (oxLDL) formation is a key cellular
stress modulating the development of atherosclerotic plaque within the
artery wall [1]. Although the role of oxLDL formation in the initiation of
atherogenesis is controversial, the cytotoxic and inﬂammatory properties
of this particle are well documented. OxLDL is readily taken up by
macrophages to form cholesterol-loaded foam cells [2,3]. Heavily
oxidized oxLDL is cytotoxic to a range of cell types, including macro-
phages [4,5]. Macrophage cell death is believed to be a key event in the
development of unstable necrotic core regions in advanced plaques [6].
The formation of oxLDL is dependent on the oxidant/antioxidant
balance within the artery wall or plaque. Macrophages appear to be a
major source of the oxidants capable of generating oxLDL including
superoxide, hypochlorite and reductants which increase the level of
fenton active metal ions on LDL [7–9]. During inﬂammation,
macrophages also release a number of chemicals with antioxidant
properties. γ-Interferon stimulation of human macrophages causes a4 3 364 2024.
. Gieseg).
e) dihydrochloride; PBS, Phos-
rived macrophages; LDL, low
l rights reserved.number of physiological and biochemical processes to occur within
the cells, including the breakdown of GTP to the pterin 7,8-
dihydroneopterin [10–12]. Neopterin is one of the oxidation products
of 7,8-dihydroneopterin and is found in the plasma and urine of
patients undergoing inﬂammatory events [13]. Plasma neopterin
levels have been shown to rise, along with C-reactive protein, as the
severity of a patient's vascular disease status increases [14–16].
In vitro, 7,8-dihydroneopterin has been found to be a potent
antioxidant. At micromolar concentrations 7,8-dihydroneopterin
inhibits reactive oxygen species damage to cells and proteins
[10,17,18], including oxLDL-induced cell death [19]. Metal ion and
aqueous peroxyl radical mediated LDL oxidation are effectively
inhibited by 7,8-dihydroneopterin. The mechanism of this inhibition
appears to involve scavenging of the lipid peroxyl radical, even though
7,8-dihydroneopterin is water soluble [20–23]. THP-1 cell-mediated
LDL oxidation is also inhibited by 7,8-dihydroneopterin but whether
the mechanism involves inhibition of cellular oxidant production or
lipid radical scavenging has not been determined [24]. Although
neopterin may thought to be the product of free radical mediated
oxidation of 7,8-dihydroneopterin, this reaction has only been
observed when hypochlorite or iodide is the oxidant [25,26]. Peroxyl
and fenton/hydroxyl radical scavenging by 7,8-dihydroneopterin has
been found to generate 7,8-dihydroxanthopterin [27]. Whether this is
also the case during cell-mediated LDL oxidation is unknown.
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formation and antioxidant loss. The role of lipid derived aldehydes in
derivatising the apoB100 protein has been well established [28–31].
The apoB100 protein moiety is responsible for the particle's stability
and receptor recognition, yet only a comparatively small number of
studies have examined the occurrence of protein oxidative events on
the apoB100. During copper and aqueous peroxyl radical (AAPH)
mediated LDL oxidation large amounts of protein hydroperoxides are
formed on LDL [22]. Protein hydroperoxides are the most abundant
reactive product produced from free radical damage to proteins [32–
34] and cells [35,36]. Up to 30% of the total hydroperoxides formed on
the LDL are protein rather than lipid hydroperoxides [22]. It is most
likely the decay of these protein hydroperoxides which generates the
observed carbonyl formation on the LDL [37]. α-Tocopherol and water
soluble 7,8-dihydroneopterin inhibit equally both the protein and lipid
hydroperoxide formation on LDL [22]. It appears that protein
hydroperoxides are formed by the reaction with lipid peroxyl radicals
during LDL oxidation. This is very different to the direct radical
reaction mechanism seen in cells and pure protein solutions where
there is little or no polyunsaturated fatty acid.
In this study, we examined the mechanism by which 7,8-
dihydroneopterin inhibits both protein and lipid oxidations during
cell-mediated LDL oxidation using the human monocyte-like THP-1
cells and human monocyte-derived macrophages.
2. Materials and methods
All solutions were prepared using high purity water from a NANOpure ultrapure
water system from Barnstead/Thermolyne (Iowa, USA). All chemicals and reagents
were AR grade or better and obtained from either the Sigma Chemical Company
(USA) or BDH Chemicals New Zealand Limited. Cell culture plasticware from Nunc
was supplied by In Vitro New Zealand Ltd. Neopterin, 7,8-dihydroneopterin and 7,8-
dihydroxanthopterin were obtained from Schirck's Laboratories, Switzerland. Phos-
phate buffered saline (PBS) solution consisted of 150 mM sodium chloride and 10 mM
sodium phosphate, pH 7.4.
Human monocyte-derived macrophages (HMDMs) were prepared using blood
donated by haemochromatosis patients at the NZ Blood Bank (Christchurch).
Monocyte isolation was achieved by density gradient centrifugation of the blood in
the presence of Lymphoprep as described by the manufacturer. Cells were then
washed four times in Hanks' Balanced Salt Solution (HBSS) before resuspension in
RPMI 1640 (containing only 5 μl/ml of heat-inactivated human serum) and incubation
at a concentration of 5×106 cells/ml in non-adherent plates for 40 h [38]. The
monocytes were subsequently resuspended in fresh RPMI 1640 (containing 10% heat-
inactivated human serum) and seeded at a concentration of 5×106 cells/ml in 12 well
adherent plates. Media were replaced every 2 to 3 days, and differentiation to human
monocyte-derived macrophages (HMDMs) occurred 10 to 20 days after the initial
isolation.
LDL was puriﬁed by buoyant density gradient ultracentrifugation from EDTA-
treated plasma collected by venapuncture from healthy male and female donors
following an overnight fast [22,39]. LDL concentration (total mass) was determined by
enzymatic cholesterol determination using the "Chol MPR 2" kit supplied by Roche
Chemicals (New Zealand), assuming an LDL molecular weight of 2.5 MDa and a
cholesterol content of 31.6% [40]. Puriﬁed LDL was desalted by dialysis against nitrogen-
gassed chelex-treated phosphate buffered saline (pH 7.4).
THP-1 cells were maintained in suspension in RPMI 1640, supplemented with 5%
heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 μg/ml streptomycin, and
incubated at 37 °C in a humidiﬁed atmosphere of 5% CO2. The THP-1 monocytes were
converted to adherent macrophage-like cells by incubating 1×105 cells/ml with 100 ng/
ml phorbol 12-myristate 13-acetate (PMA) in standard six well plates for 7 days [41].
Immediately prior to an experiment, the cells were washed three times with warm
PBS before the addition of Ham's F10 medium supplemented with either 1.5 μM FeSO4
for THP-1 cells oxidation or 4.5 μMFeSO4 and 10 nM CuCl2 for HMDM cells. Dialysed LDL
was added to give a ﬁnal concentration of 100 μg/ml (total mass) before incubating at
37 °C in the CO2 incubator.
Atherosclerotic plaque material was surgically removed from patients undergoing
carotid or femoral artery endarterectomy at Christchurch Hospital, New Zealand. The
excised plaque material was placed on ice within 10 min of removal before being
transferred to the University of Canterbury and frozen at −80 °C. The time between
removal and freezing at −80 °C was less than 40 min. The frozen tissue was analysed
within 3 months of collection. For analysis, frozen plaque was sectioned with a
scalpel and then ground to a powder in a pestle and mortar under liquid nitrogen.
The frozen powder was then transferred to a glass test tube to which 5 ml of water
containing EDTA and BHT was added, before being homogenised using a tissumizer
(Tekmar Ltd, USA) for 30 s. The homogenate was then analysed for total neopterin as
described below.LDL protein hydroperoxide formation was measured by FOX analysis which
measures the peroxide oxidation of ferrous ions to ferric ions as previously described
[22,42]. Brieﬂy, trichloroacetic acid (TCA) was added to a sample of the media to
precipitate the LDL. The resulting pellet was washed in 1:1 chloroform:methanol before
centrifugation, drying under vacuum and suspended in 900 μl of 50% v/v glacial acetic
acid to which was added 50 μl each of xylenol orange and ferrous ammonium sulphate
(both 5 mM in 25 mM sulphuric acid). Samples were incubated in the dark at room
temperature for 30 min and the absorbance measured at 560 nm against a water blank.
An extinction co-efﬁcient of 48,000 M−1 cm−1 was used to calculate the protein
hydroperoxide concentration [42].
Protein carbonyls were measured by derivitization with 2,4-dinitrophenyl
hydrazine (DNPH) and spectrophotometric measurement at 360 nm [43]. Samples
were incubated for 90 min at 37 °C with 1 ml DNPH (in 2 M hydrochloric acid) before
centrifugation. The resulting pellet was washed twice in ethanol:ethyl acetate (1:1)
before resuspending in 6 M guanidine hydrochloride (in 2 M hydrochloric acid).
Following a 60 minute incubation in the dark at room temperature, the absorbance of
the supernatant was measured at 360 nm against controls incubated in the absence of
DNPH. Carbonyl concentrations were calculated using the extinction co-efﬁcient of
21,000 M−1 cm−1 [43].
LDL lipid peroxidation was measured by HPLC-TBARS analysis [44] using reverse
phase high performance liquid chromatography (HPLC) with ﬂuorescence detection as
previously describe [27]. Further oxidation during analysis was prevented by the
addition of BHT (inmethanol) to all samples to give a ﬁnal concentration of 1.3mg/ml in
the TBARS incubation mixture [45].
α-Tocopherol (vitamin E) was determined by reverse phase HPLC with ﬂuorescence
detection of hexane extracts of incubation media [20,46].
Loss of 7,8-dihydroneopterin and 7,8-dihydroxanthopterin formation in tissue
culture media was determined by reverse phase HPLC with electrochemical detection
[47]. Samples were deproteinated by TCA precipitation and 10 μl of supernatant
injected into a Develosil C18, 250 mm×4.6 mm column supplied by Phenomenex.
The mobile phase of 5% methanol in 20 mM ammonium phosphate (pH 6) was
pumped through the column at 1 ml/min and the eluent monitored using a
Shimadzu L-ECD-6A electrochemical detector with a glass carbon detector set a
+0.6 V. Total neopterin levels (neopterin+7,8-dihydroneopterin) in plaque were
determined by oxidising the 7,8-dihydroneopterin to neopterin using acidic iodide
solution before HPLC analysis, as described above, except that the neopterin was
detected using a Shimadzu RF-10Axls ﬂuorescence detector set at excitation 353,
emission 438. The concentration and identity of the eluted neopterin, 7,8-
dihydroneopterin and 7,8-dihydroxanthopterin were conﬁrmed by comparison to
standards.
Superoxide reduction of nitroblue tetrazolium (NBT) in the presence and absence of
superoxide dismutase over a 2 hour incubation period in HBSS media was used to
measure cellular superoxide release [48].
Thiol levels in the media were measured by reaction with 5,5′-dithiobis (2-
nitrobenzoic acid) (DTNB) to generate 3-carboxylato-4-nitrothiophenolate (CNTP)
which absorbs at 412 nm [49].
Trans-plasma membrane electron transport (TPMET) reduction of copper and iron
ions was determined using the method of Baoutina et al. [50]. Cell-mediated reduction
of Cu+2 to Cu+1 was measured by incubating the cells in HBSS containing bathocuproine
disulphonic acid (BCS) for 2 h. After removal of cells, the Cu+1-BCS complex was
measured at 482 nm, against cell free controls. Ferric ion reduction was measured by
incubating cells in HBSS containing potassium ferricyanide for 2 h. After removal of cells
the mediumwas incubated for 10 min with citric acid, sodium acetate, citric acid, ferric
chloride and bathophenanthroline disulphonic acid (BPS) and the absorbance
measured at 535 nm against cell free controls [50].
The data was analysed using the Prism software package, supplied by Graphpad
Software Inc. Statistical signiﬁcance was conﬁrmed by a one-way analysis of variance
(ANOVA) followed by Tukey's multiple comparison test. Where appropriate, signiﬁ-
cance is indicated on ﬁgures as ⁎⁎⁎pb0.001; ⁎⁎pb0.01; and ⁎pb0.05. Results shown are
from single experiments, representative of a minimum of three, and are expressed as
mean±SEM of triplicate treatments.
Collection and analysis of the plaque were by patient consent under the ethics
approved by the Upper South B Regional Ethics Committee, ethics approval number 01/
04/036. Collection of blood for the puriﬁcation of monocytes and low density
lipoprotein received ethical approval from the Upper South A Regional Ethics
Committee, ethics approval number 98/07/069.
3. Results
In the presence of both THP-1 cells (Fig. 1A) and HMDM cells (Fig.
1B), protein hydroperoxide formation and lipid oxidation on LDL were
tightly correlated (r2=0.99). The LDL oxidation mediated by both cell
types displayed the classic lag phase period during which α-
tocopherol was lost before the formation of signiﬁcant levels of lipid
and protein hydroperoxides. With THP-1 mediated LDL oxidation,
twice as much lipid peroxide derived TBARS was formed as number of
moles of protein hydroperoxide detected, whilst for human mono-
cyte-macrophage mediated LDL oxidation, TBARS and protein
Fig. 1. Formation of oxidant products during cell-mediated LDL oxidation. Either (A)
adherent THP-1 macrophage-like cells (1×105/ml) in Ham's F10 supplemented with
1.5 μM FeSO4 or (B) HMDMs (1×106/ml) in Ham's F10 supplemented with 4.5 μM FeSO4
and 0.01 μM CuCl2 were incubated at 37 °C with 0.1 mg/ml LDL. At indicated time points
samples were taken and analysed for α-tocopherol (○), protein hydroperoxides (□) or
lipid oxidation-TBARS (■). No increase in protein hydroperoxides or TBARS was
observed with cells alone or in cell free incubations.
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This was the only signiﬁcant difference in LDL oxidation observed
between the two cell types.
Comparison of protein carbonyl and protein hydroperoxide
formation during THP-1 cell-mediated LDL oxidation showed that
the two oxidation products shared similar kinetics (Fig. 2). NeitherFig. 2. Comparison of LDL protein carbonyl and hydroperoxide levels during THP-1 cell-
mediated LDL oxidation. Adherent THP-1 macrophage-like cells (1×105/ml) in Ham's
F10 supplemented with 1.5 μM FeSO4 were incubated at 37 °C with 0.1 mg/ml LDL.
Samples of the media were taken at various time points and analysed for protein
hydroperoxides (□) or protein carbonyls (●).protein oxidation species was detected until after the end of the lag
period, at which time both oxidation products began to rapidly form.
The protein hydroperoxides peaked at 6 h before slowly decaying.
Three hours after the protein hydroperoxide peak, the carbonyl levels
reached a maximum concentration and did not rise further. The
slower rise in protein carbonyls compared to protein hydroperoxides
is consistent with the hypothesis that a signiﬁcant proportion of the
protein hydroperoxides decays into protein carbonyls [51]. No
dityrosine was observed during the LDL oxidation but a small amount
of protein-bound DOPA (290 mmol per mol of LDL) was observed by
the end of the propagation phase.
The addition of 7,8-dihydroneopterin to the cell incubation media
caused a clear inhibition of THP-1 cell-mediated LDL oxidation by
extending the length of the LDL oxidation lag phase without altering
the rate of the latter propagation phase (Fig. 3). During this extendedFig. 3. Inhibition of THP-1 cell-mediated LDL protein and lipid oxidation by 7,8-
dihydroneopterin. Adherent THP-1macrophage-like cells (1×105/ml) were incubated at
37 °C in Ham's F10 supplemented with 1.5 μM FeSO4. Varying concentrations of 7,8-
dihydroneopterin were added to the incubation 5 min before the addition of 0.1 mg/ml
LDL. Samples of themediawere taken at various time points and analysed for (A) protein
hydroperoxides, (B) lipid oxidation (HPLC-TBARS) and (C) α-tocopherol loss. The 7,8-
dihydroneopterin concentrations were: (■) 0 μM; (●) 10 μM (□) 20 μM; and (○) 50 μM.
Fig. 5. 7,8-Dihydroneopterin oxidation during protein, lipid and tocopherol oxidations
by THP-1 cells. Adherent THP-1 macrophage-like cells (1×105/ml) were incubated at
37 °C, with 0.1 mg/ml LDL and 20 μM 7,8-dihydroneopterin, in Ham's F10 supplemented
with 1.5 μM FeSO4. At various time points, 7,8-dihydroneopterin loss (●) was compared
to (A) the formation of protein hydroperoxides (□) and TBARS (■) and (B) the loss of α-
tocopherol (○).
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Even the lowest concentration examined, 10 μM, extended the lag
phase by 3 h. The increase in lag phase appeared to be proportional to
the 7,8-dihydroneopterin concentration up to 20 μM. This relationship
between lag phase and 7,8-dihydroneopterin is consistent with
previous studies investigating copper or aqueous peroxyl radical
(AAPH) mediated LDL oxidation [20,22]. The rate of α-tocopherol loss
was signiﬁcantly reduced by the presence of 7,8-dihydroneopterin
(Fig. 3C), indicating that the 7,8-dihydroneopterin was either scaven-
ging the chain propagating lipid peroxyl radical, or inhibiting the
activity of the cell-derived oxidant. This is further supported by the
fact that the protein and lipid oxidations remained tightly coupled
during both the lag phase and subsequent propagation phase (Figs. 1
and 3). Protein hydroperoxides in LDL appear to be formed by a
reaction of the lipid peroxyl radicals with apoB100 [22]. The
requirement for lipids during THP-1 cell-mediated protein hydroper-
oxide formation was further demonstrated by the lack of protein
hydroperoxides generated on albumin incubated with THP-1 cells in
Ham's F10 media for up to 36 h (data not shown).
7,8-Dihydroneopterin was also observed to inhibit HMDM cell-
mediated oxidation, with 100 μM 7,8-dihydroneopterin completely
preventing the loss of α-tocopherol and peroxidation of both lipids
and proteins during an extended 18 hour incubation (Fig. 4).
The complete loss of 7,8-dihydroneopterin from the cell culture
media was observed to coincide with the formation of lipid and
protein hydroperoxides (Fig. 5A). A comparison of 7,8-dihydroneop-
terin and α-tocopherol loss shows both antioxidants being consumed
at the same time, suggesting that they react at similar rates and with
the same oxidant (Fig. 5B). The initial difference between 7,8-
dihydroneopterin and α-tocopherol loss may be due to a small
difference in reaction rates and initial concentrations.
The oxidative loss of 7,8-dihydroneopterin from the culture media
required the presence of both cells and LDL (Fig. 6A). Only 10% of the
7,8-dihydroneopterin was oxidised over a 12 hour period in the
presence of the THP-1 cells alone. Consistent with this, superoxide, an
oxidant scavenged by 7,8-dihydroneopterin, was not released from
either the adherent THP-1 or HMDM cells in Ham's F10 media as
measured by cytochrome c or nitroblue tetrazolium reduction analysis
(data not shown). This data further suggests that the 7,8-dihydro-
neopterin is scavenging an oxidant located in the LDL, possibly the
lipid peroxyl radical.
The main product of the 7,8-dihydroneopterin LDL oxidation
was not neopterin but 7,8-dihydroxanthopterin. HPLC analysis of
the media with electrochemical detection clearly showed theFig. 4. HMDM cell-mediated LDL oxidation and inhibition by 7,8-dihydroneopterin.
HMDMs (1×106/ml) were incubated at 37 °C in Ham's F10 supplemented with 4.5 μM
FeSO4 and 0.01 μM CuCl2. Increasing concentrations of 7,8-dihydroneopterin were
added to the cell cultures before the addition of 0.1 mg/ml LDL and incubated for 18 h.
The concentration of protein hydroperoxides (□), TBARS (■) and α-tocopherol (○) in
the media was determined as described in Materials and methods.formation of signiﬁcant amounts of 7,8-dihydroxanthopterin at
the same time as 7,8-dihydroneopterin was being oxidised (Fig. 6B).
Similar to the loss of 7,8-dihydroneopterin, the rate of 7,8-
dihydroxanthopterin formation was greatly enhanced by the
presence of both cells and LDL.
The data suggests that 7,8-dihydroneopterinwas inhibiting the LDL
oxidation by competing with α-tocopherol for the same chain
propagating oxidant, the lipid peroxyl radical. It was possible that
the reaction rates were masking a direct down-regulation of cell-
generated oxidants or a scavenging of these primary oxidants/radicals.
LDL oxidation in a number of systems has been shown to be
dependent on metal ion reduction either by thiols [52] or a
transplasma membrane electron transport system (TPMET) [50]. In
our experimental system, cell-mediated LDL oxidation required
supplementation of the Ham's F10 media with iron. The reduction of
this iron was unlikely to be due to thiol release. DTNB analysis of the
culture media failed to show any increase in thiol levels, suggesting
that a TPMET system was operating. Analysis of the culture media
showed that the THP-1 and HMDM cells were reducing signiﬁcant
amounts of iron and copper ions (data not shown). As 7,8-
dihydroneopterin is a reasonable reducing agent, it was not possible
to observe inhibition of this process directly. Instead, THP-1 cells or
HMDM cells were pre-incubated with 50 μM 7,8-dihydroneopterin
before being placed in fresh media to measure the rate of copper or
iron reduction. These experiments failed to show any change in the
metal ion reduction rate, suggesting that 7,8-dihydroneopterin
functions by interacting directly with the LDL particle during
oxidation.
Table 1
Total neopterin levels in atherosclerotic plaques
I.D. Plaque
location
Total neopterin
(μM)
Age Sex Stenosis
(%)
Smoking
status
Medication
Statin Aspirin
A Left CB 1.59 71 M 80 Ex Yes Yes
B Left CB 1.79 64 F 80 Unknown Yes Yes
C Left CB 1.26 72 F 90 No No Yes
D Left CB 0.92 67 M 80 No No Yes
E Right CB 0.72 76 M 80–95 No Yes Yes
F Left FB 2.34 73 M 75 Yes No No
G Right FB 1.57
Plaques were removed from patients' carotid artery bifurcation (CB) or femoral artery
bifurcation (FB) during endarterectomy at Christchurch Hospital, New Zealand. The
excised plaques were frozen at −80 °C before being homogenised and analysed by HPLC
for neopterin as described in Materials andmethods. 7,8-Dihydroneopterinwas oxidised
to neopterin so data represents the total neopterin level (neopterin+7,8-dihydroneop-
terin). All plaques examined were advanced calciﬁed plaques. All plaque donors were
being treated for high blood pressure. Plaques F and G were taken from the same
patient.
Fig. 6. 7,8-Dihydroneopterin is oxidised to 7,8-dihydroxanthopterin by LDL-derived
radicals. 20 μM 7,8-dihydroneopterin was dissolved in Ham's F10 supplemented with
1.5 μM FeSO4 and incubated at 37 °C, either alone (□), with 1×105/ml THP-1 cells (○) or
with 0.1 mg/ml LDL and THP-1 cells (■). Samples were analysed by HPLC at various time
points for the (A) loss of 7,8-dihydroneopterin and (B) formation of 7,8-dihydrox-
anthopterin. Neopterin formation during the incubation was not signiﬁcant.
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and has been shown to inhibit superoxide synthesis in some cells [53].
As neopterin is a poor reducing agent it was added directly to the cell
incubation media whilst measuring metal ion reduction. Neopterin
was found to have no effect on the cell's TPMET metal ion reduction
activity, nor was it found to have any effect on the cell-mediated LDL
oxidation (data not shown).Fig. 7. Total neopterin synthesis and release by HMDM cells. HMDMs (1×106 cells/ml)
were incubated at 37 °C in RPMI supplemented with 10% heat-inactivated human serum
and 500 U/ml IFN-γ. At various time points, total neopterin (neopterin plus 7,8-
dihydroneopterin) levels were measured in the supernatant (■) and cell lysate (□).Treatment of HMDM cells with γ-interferon for up to 48 h in
human serum-supplemented RPMI-1640 failed to generate more than
20 nM total neopterin (7,8-dihydroneopterin+neopterin) in themedia
or 80 pmol total neopterin/mg protein within the cells (Fig. 7). In the
presence of THP-1 cells incubated with 500 U/ml γ-interferon, the
maximum levels after 48 h were 23 nM in the media and 48.9 pmol/
mg protein within the cells. No neopterin/7,8-dihydroneopterin was
observed in the absence of γ-interferon. Only total neopterin was
measured for this analysis as the low level of 7,8-dihydroneopterin
made it too labile for accurate measurement. We therefore converted
all the 7,8-dihydroneopterin to neopterin by iodide oxidation and
subsequently measured total neopterin. The concentration of neop-
terin measured was well below that at which 7,8-dihydroneopterin
antioxidant activity has been observed. The addition or removal of
iron from the media had no signiﬁcant effect on the pterin levels
raising the question of what is the in vivo concentration of pterins
within plaques.
Six atherosclerotic plaques were collected during endarterectomy
surgery from either the carotid bifurcation or the femoral artery. The
patients' ages ranged between 63 and 73 and all were being treated for
high blood pressure (Table 1). The 7,8-dihydroneopterin was found to
be relatively labile during plaque analysis sowe chose tomeasure total
neopterin by once again oxidising all the 7,8-dihydroneopterin to
neopterinwith iodide. The total neopterin concentrationwas found to
range between 0.92 and 2.34 μM, which is just below the concentra-
tion that 7,8-dihydroneopterin's antioxidant activity has been
observed. The total neopterin concentration within the plaques
examined is between 46 and 110 times higher than that observed in
tissue culture.
4. Discussion
A number of pteridines have been shown to directly interact with
cells. Both neopterin and 7,8-dihydroneopterin have been found to
induce apoptosis in T-cells at varying concentrations [54]. Exogenous
neopterin has been reported to cause cardiac contractile dysfunction
in isolated perfused hearts [55], stimulate angiogenic growth factor
release from human ovarian carcinoma cells [56], and inhibit NADPH
oxidase activity in rat peritoneal macrophages [53]. This study found
little evidence of 7,8-dihydroneopterin directly interacting with
macrophages to inhibit LDL oxidation. Signiﬁcant oxidation of 7,8-
dihydroneopterin only occurred in the presence of both cells and LDL
(Fig. 6). Furthermore, the propagation phase of LDL oxidation began
only after the loss of 7,8-dihydroneopterin and α-tocopherol. It
therefore appears that 7,8-dihydroneopterin inhibits the lipid and
protein LDL oxidation propagation phase by scavenging a key oxidant
on the LDL. This study and previous studies suggest that the key
1100 C.A. Firth et al. / Biochimica et Biophysica Acta 1783 (2008) 1095–1101oxidant is the chain propagating lipid peroxyl radical [20,22,24]. It is
unlikely that 7,8-dihydroneopterin inhibits or scavenges the primary
radical-generating process within the cells. Ascorbate has been shown
to reduce the α-tocopherol radical back to α-tocopherol during LDL
oxidation [57,58]. 7,8-Dihydroneopterin did not regenerate the α-
tocopherol but competed with it for the lipid peroxyl radical. This was
previously observed during copper and AAPH peroxyl radical
mediated LDL oxidation [20,22]. In the initial stages of the cell-
mediated LDL oxidation, the molar excess of 7,8-dihydroneopterin
over α-tocopherol appears to have out competed the α-tocopherol for
the peroxyl radical (Fig. 5B). Once the level of 7,8-dihydroneopterin
decreased sufﬁciently, α-tocopherol and 7,8-dihydroneopterin oxida-
tion appeared to occur simultaneously.
The protection of both lipid and protein within the LDL particle
further supports a lipid peroxyl radical scavenging mechanism for the
7,8-dihydroneopterin. We have previously shown that during chemi-
cal oxidation of LDL, protein hydroperoxide formation is dependent on
lipid peroxidation [22]. Other studies have also shown lipid oxidation
causing amino acid loss [59] and carbonyl formation [60]. With LDL,
lipid peroxidation has been correlated with apoB100 carbonyl
formation in the presence of copper ions [61]. It would appear that
protein oxidation and protein hydroperoxide formation are a
signiﬁcant process in LDL oxidation. The reactive nature of protein
hydroperoxides suggests that they may contribute to the cytotoxicity
of oxLDL. OxLDL causes the rapid loss of cellular thiols [19,62], just as
protein hydroperoxides are known to react with glutathione and
protein thiols [32].
Previous studies suggested that neopterin might be the product
of 7,8-dihydroneopterin oxidation during LDL oxidation [20] but
this study clearly shows that 7,8-dihydroxanthopterin is the
primary product. 7,8-Dihydroxanthopterin has been detected in
the urine of patients with malignant hyperphenylalaninemia and
phenylketonuria [63] but whether it occurs in the plasma of
patients with chronic or acute inﬂammation is unknown. 7,8-
Dihydroxanthopterin appears to have no further effect on LDL
oxidation as the presence or absence of 7,8-dihydroneopterin did
not alter the rate of lipid or protein oxidation during the
propagation phase.
Plasma neopterin concentration rarely rises above 100 nM during
inﬂammation, well below the levels required for physiological activity,
though neopterin has been shown to have pro-inﬂammatory effects
with non-macrophage-like cells [10,64]. The source of this neopterin
is believed to be activated macrophages within the inﬂammatory site.
The neopterin released from the cells is thought to be diluted down to
the nanomolar concentration seen in the plasma. This suggests that
the extracellular concentration of neopterin/7,8-dihydroneopterin at
an inﬂammatory site is much higher than that seen in the plasma. We
here have conﬁrmed that the concentration of total neopterin can
reach micromolar concentrations within advanced atherosclerotic
plaques. At these concentrations 7,8-dihydroneopterin would have
antioxidant activities, especially at the low radical ﬂuxes expected
within tissues. Unfortunately we were unable to reproduce this
concentration of 7,8-dihydroneopterin or neopterin during tissue
culture studies, suggesting that in addition to γ-interferon there are
other factors affecting 7,8-dihydroneopterin synthesis within the cell.
Within the plaques examined we were unable to detect signiﬁcant
amounts of 7,8-dihydroneopterin. It is possible that within these
extremely advanced calciﬁed plaques, 7,8-dihydroneopterin had been
oxidised, possibly to neopterin, the main pterin we detected.
Hypochlorite is currently the only know oxidant found in vivo which
can oxidise neopterin to 7,8-dihydroneopterin [26,27]. Chlorinated
compounds have been detected within atherosclerotic plaques
suggesting that hypochlorite is a signiﬁcant oxidant formed during
atherogenesis [65,66]. Neutrophils generate large amounts of hypo-
chlorite but human macrophages have also been shown to be a source
of this oxidant [67]. The balance between 7,8-dihydroneopterin andoxidants such as hypochlorite may be a key factor in determining the
development of advanced atherosclerotic plaques.
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